BSX:NYSE (USA) Also trade in: Germany

Boston Scientific Corp

$ 35.89 0.96 (2.75%)
Volume: 13,695,812 Avg Vol (1m): 7,712,742
Market Cap $: 49.72 Bil Enterprise Value $: 56.63 Bil
P/E (TTM): 30.04 P/B: 5.68
Earnings Power Value 14.14
Net Current Asset Value -5.98
Tangible Book -4.02
Projected FCF 9.9
Median P/S Value 15.91
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

Current vs industry vs history
Cash-to-Debt 0.02
Equity-to-Asset 0.42
Debt-to-Equity 0.81
Debt-to-EBITDA 3.12
Interest Coverage 6.92
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.57
DISTRESS
GREY
SAFE
Beneish M-Score -2.12
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 14.07%
WACC 6.91%

Profitability & Growth : 8/10

Current vs industry vs history
Operating Margin % 16.91
Net Margin % 17.01
ROE % 21.53
ROA % 8.42
ROC (Joel Greenblatt) % 77.90
3-Year Total Revenue Growth Rate 9.50
3-Year Total EBITDA Growth Rate 85.10

» BSX's 30-Y Financials

Financials (Next Earnings Date: 2019-04-24)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:BSX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Devices » Medical Devices    NAICS : 339112    SIC : 3841
Compare NAS:ISRG NYSE:EW NYSE:ZBH NAS:ALGN LSE:SN. NYSE:SYK NAS:ABMD NYSE:TFX XSWX:SOON NYSE:VAR SZSE:300003 OCSE:WDH XPAR:DIM ASX:COH LSE:CTEC NZSE:FPH NYSE:GMED OCSE:AMBU B NAS:IART OCSE:GN
Traded in other countries
Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract tests, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Ratios

Current vs industry vs history
PE Ratio (TTM) 30.04
Forward PE Ratio 21.98
N/A
PE Ratio without NRI 30.04
Price-to-Owner-Earnings 25.03
PB Ratio 5.68
PS Ratio 5.10
Price-to-Operating-Cash-Flow 161.81
EV-to-EBIT 34.07
EV-to-EBITDA 25.06
EV-to-Revenue 5.77
PEG Ratio 0.78
Current Ratio 0.76
Quick Ratio 0.54
Days Inventory 141.29
Days Sales Outstanding 59.75
Days Payable 44.20

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -0.90

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 3.61
Price-to-Median-PS-Value 2.25
Earnings Yield (Joel Greenblatt) % 2.92
Forward Rate of Return (Yacktman) % -15.68

More Statistics

Revenue (TTM) (Mil) $ 9,823
EPS (TTM) $ 1.19
Beta 0.82
Volatility % 18.73
52-Week Range $ 27.91 - 41
Shares Outstanding (Mil) 1,390.5

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y